Eric Palmer

Biography for Eric Palmer

Eric Palmer, Senior Editor

Eric Palmer is a business and technology journalist with more than three decades of prize-winning experience as a reporter and editor with daily, weekly, monthly and online publications. He was healthcare reporter for The Kansas City Star before becoming deputy business editor for the daily newspaper. He spent eight years as editor of The Kansas City Business Journal, which had a strong emphasis on the healthcare industry. On the personal side, he is an avid fly fisherman, cooks and collects wine, and likes to travel with his family. Eric is based in Kansas City and can be reached at

Articles by Eric Palmer

Celltrion's biosimilar of J&J's Remicade reviewed favorably by FDA staffers

FDA staff reviewers were supportive of the Remicade biosimilar from Celltrion ahead of next week's advisory committee meeting. The reviewers said that the drug is "highly similar" to the branded product in terms of safety, purity and potency. 

AstraZeneca CEO still interested in M&A but he is getting very picky

AstraZeneca recently plunked down $575 million to get from Takeda global rights to the chronic obstructive pulmonary disease (COPD) treatment Daxas. It was the kind of deal that currently intrigues CEO Pascal Soriot, something that will immediately pay off and which falls into one of the three areas around which he is trying to rebuild the company.

FDA's Califf calls for 'sweeping re-examination' of policies in effort to fight opioid abuse

The FDA has been repeatedly criticized for expanding approvals for opioids in the face of an "epidemic" of abuse and overdoses. Today Dr. Robert Calif, President Obama's pick to head the agency, took that matter head-on, calling for a sweeping review of the agency's policies.

UPDATED: Gilead's hep C juggernaut continues in Q4, even as U.S. sales fall

Gilead Sciences and its hep C juggernaut continued to churn out big sales in Q4 and bested Wall Street expectations, but it took strong growth overseas to overcome an expected falloff of sales of Sovaldi and Harvoni in the U.S.

Was Allergan's CEO simply touting a Texas plant expansion--or nudging watchdogs on Pfizer merger, too?

Allergan's $160 billion inversion merger with Pfizer and its attendant whacking of U.S. taxes has raised some hackles in Washington. Now, Allergan seems to be offering a bit of sugar to make the tax-avoiding medicine go down by talking about doubling employment at its flagship plant in Texas.

Struggling Eisai gets FDA approval for cancer drug Halaven for liposarcoma

Japan's Eisai got a much-needed boost on Thursday when the FDA approved its cancer drug, Halaven, for treatment of liposarcoma for patients in which the cancer has advanced to the point where surgery is not an option.

UPDATED: Amgen beats in Q4 as established drugs come through

Amgen had a steady stream of significant new drug approvals in 2015, like the FDA nod for its Repatha which is in a new class of cholesterol fighters that are expected to generate significant sales. But Repatha and several others are too early in their launch to register separately on the sales line, and it was growth in sales of Amgen's tried-and-true drugs that allowed the biotech to breeze by analyst expectations.

Gilead Sciences' John Martin stepping out of CEO role after two decades, is replaced by John Milligan

John Martin, who has led Gilead Sciences through two decades of incredible growth and more recently significant controversy over the pricing it is hep C cures, is stepping up and out of the CEO role. President John Milligan has been named CEO as Martin moves up to the executive chairman of the board.

Revved-up Tecfidera sales power Biogen in Q4

Biogen CEO George Scangos and his team tamped down investor expectations earlier this month at the J.P. Morgan Healthcare Conference, saying that the company faced headwinds. But the drugmaker got those winds into its sails, and sales, this quarter, racing past Wall Street expectations as MS med Tecfidera regained the momentum lost earlier last year.

Novartis adds 100 jobs at Lek site in Slovenia as it muscles up on biosimilars

Novartis was the first drugmaker to get a biosimilar approved in the U.S. and has set itself up to be a major player in the growth of the biologic copies. That is going to require more development muscle, and so it has expanded its Lek subsidiary in Slovenia, adding 100 jobs in the process.